Viewpoint Molecular Targeting to merge with Isoray Inc.

Coralville-based Viewpoint Molecular Targeting, a radiopharmaceutical company developing alpha-particle therapies and diagnostic imaging agents, is expected to merge with Isoray Inc., a medical technology company specializing in seed brachytherapy and headquartered in Richland, Washington.

According to the terms of the agreement, a newly formed wholly owned subsidiary of Isoray will merge with and into Viewpoint, with Viewpoint continuing as the surviving corporation and a subsidiary of Isoray.

“I believe the…